Recall Alert
| Drug products declared Substandard/Adulterated by Drug Testing laboratories Punjab |
| DRAP Alert No | No II/S/11-26-55 |
| Action Date | 16th November, 2026 |
| Target Audience | – National Regulatory Field Force – Healthcare Professional – Physician, Pharmacist, and Nurses at hospitals – General Public |
| Problem / Issue | Drug Testing Laboratories (DTL) of Punjab Province informed that the samples of below mentioned drug products have been declared as ‘Substandard/Adulterated. Following are the details: |
| Sr. No. | Product Name | Name of Manufacturer/Importer | Batch Number | Remarks |
| 1 | Zeftrox Injection 500mg Each vial contains Ceftriaxone Sodium USP equivalent to 500mg of Ceftriaxone | Zafa Pharmaceuticals Laboratories (Pvt.) Limited, Plot No. B-10, Block-B, S.I.T.E., North Karachi, Karachi. | 677 | The Sample is declared as “SUB-STANDARD” on the basis of Sterility Test by Drug Testing Laboratory, Faisalabad. |
| 2 | Davidax Injection 4mg/ml Each ml contains: Dexamethasone Sodium Phosphate USP equivalent to Dexamethasone Phosphate 4 mg. | UNISON Chemical Works, 15Km, Raiwind Road, Lahore. | DDI 126 | The sample is declared as “ADULTERATED” as per Section 3(a)(iv) of The Drug Act 1976 by Drug Testing Laboratory, Faisalabad. |
| 3 | Dormicum Injection 5mg/5ml Each ampule contains: Midazolam (Ph.Eur) 5mg/5ml | Martin Dow Marker Ltd, 7, Jail Road, Quetta. | 47447 & 47661 | The above sample is declared as “SUB-STANDARD” on the basis of Visible Particulate Matter Drug Testing Laboratory, Lahore. |
Therapeutic Goods (s) Affected: –
| Risk Statement: | The use of these substandard and adulterated injectable products poses serious health risks, including treatment failure, severe infections, hypersensitivity reactions, and potential life-threatening complications due to lack of sterility, incorrect active ingredients, or presence of particulate matter. |
| Action Initiated | The field force of Provincial Drug Control Departments have been asked to immediately conduct market surveys for detection of presence and removal of the affected batches from the market. Manufacturers, importers and distributors have been directed to initiate recall of the affected batches in accordance with applicable regulatory requirements. |
| Advice for Healthcare Professionals | DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned batches of the drug product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link. |
| Advice for Pharmacies/Medical stores: – | All pharmacists and chemists working at distributions and pharmacies should immediately check their stocks and stop supplying the above-mentioned batches. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units should also increase surveillance in the market to ensure effective recall of the affected products. |
| Advice for Consumers | Consumers and healthcare facilities in possession of the affected batches should immediately stop using the above-mentioned products and contact the supplier, distributor or manufacturer for return or replacement. Any adverse event or quality issue associated with the use of these products should be reported to DRAP/National Pharmacovigilance Centre. |
